AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02204176 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercise info
Description: Discussion:~* benefits of exercise~* types of exercise~* exercise guidelines~* components of an exercise session~* how to reduce risk of injuries
Study NCT02204176 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation intentions
Description: Discussion of:~* barriers to exercise and how to address/overcome barriers~* how to create detailed exercise plans
Study NCT02204176 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Industriousness
Description: Discussion of:~* realistic monitoring of efforts related to exercise~* reaching and pushing past thresholds for sustained effort for exercise
Study NCT02204176 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pedometer
Study NCT02204176 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: pedometer
Study NCT01716117 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surpass Flow Diverter
Description: Treatment of an intracranial aneurysm involves the placement of a specially designed metallic mesh tube in a vessel in the brain where an aneurysm is located. The device looks like a fishnet sock with both ends open. Each device is delivered through a small catheter (a long, flexible tube). The catheter containing the device is inserted and advanced into a vessel in the brain. The device is then placed in the brain vessel by releasing it from the catheter. Once the device is placed inside the brain vessel, it is intended to reinforce the area of the vessel that is weakened and bulging (the aneurysm), and to cause blood to flow down the vessel and away from the aneurysm while allowing blood in the aneurysm to clot. This procedure is called an endovascular aneurysm treatment because the device is delivered through the blood vessels.
Study NCT03702556 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI scan
Description: 7.0 tesla functional MRI scan
Study NCT01950026 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryotherapy application
Description: * Height, weight and BMI verification~* subjects in supine position after 20 minutes of resting~* cryotherapy application by cold thermal bag (thermoGel brand) size P~* 15-20 cm above the ASIS~* temperature verified before and after cryotherapy application with an infrared thermometer CA 380 CASON brand, Brazil
Study NCT00321113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: immunosuppression
Study NCT00321113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: immunosuppression
Study NCT00321113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil
Description: oral
Study NCT00321113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: oral
Study NCT00321113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: steroids
Description: oral
Study NCT03867058 — intervention group
Intervention type: BEHAVIORAL
Intervention: Electrode selection/electrode configuration
Description: Electrodes will be chosen based on their spatial tuning curves. Focused stimulation will be applied to electrodes with good temporal processing acuity.
Study NCT04187053 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional mechanical therapy
Description: Both experimental and sham arms will receive the Conventional mechanical therapy
Study NCT04187053 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Conventional mechanical therapy
Description: Both experimental and sham arms will receive the Conventional mechanical therapy
Study NCT04187053 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: Sham group will receive saline as a sham for methylene blue
Study NCT04187053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: Experimental arm will receive methylene blue
Study NCT04187053 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light emitting laser
Description: Experimental arm will receive Light emitting laser
Study NCT04187053 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Non-light emitting laser
Description: Sham group will receive Non-light emitting laser
Study NCT03642951 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Treatment
Description: The study patients will be randomly assigned to two groups, each consisting of 10 patients: Group A - patients stimulated by devices marked A; Group B - patients stimulated by devices marked B. Since the devices used for actual and sham stimulation (placebo control) are similar in all respects including external appearance and the sound produced while activated, the technician(s), investigators and the patients will be completely blind to whether actual or sham stimuli are being delivered, i.e. whether Group A or Group B patients are receiving the actual stimuli. Indeed, both devices marked A\&B could be used to deliver either type of stimuli. Only the person who constructed the devices will know which is which. Therefore, this study will be a truly randomized double-blinded placebo-controlled clinical trial. In case of emergency, un-blinding of the device will be available to the study team via a sealed envelope, stored with the study documents, separate from the subjects study files.
Study NCT03642951 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Treatment
Description: The study patients will be randomly assigned to two groups, each consisting of 10 patients: Group A - patients stimulated by devices marked A; Group B - patients stimulated by devices marked B. Since the devices used for actual and sham stimulation (placebo control) are similar in all respects including external appearance and the sound produced while activated, the technician(s), investigators and the patients will be completely blind to whether actual or sham stimuli are being delivered, i.e. whether Group A or Group B patients are receiving the actual stimuli. Indeed, both devices marked A\&B could be used to deliver either type of stimuli. Only the person who constructed the devices will know which is which. Therefore, this study will be a truly randomized double-blinded placebo-controlled clinical trial. In case of emergency, un-blinding of the device will be available to the study team via a sealed envelope, stored with the study documents, separate from the subjects study files.
Study NCT03068663 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sampling
Description: Patients will receive their standard treatments, surgery with/without chemotherapy. A patient intervention consists in taking samples of blood, saliva, faeces, lung/tumour tissue, and bronchoalveolar lavage fluid.
Study NCT00517907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preimplantation factor (PIF-1)
Description: The study will include 6 patients and will last for at least six months. The first three patients will receive PIF-1 (0.5 mg/kg/day for 14 days) by subcutaneous injection. The dosage in the next three patients may be increased to 1 mg/kg/day for 14 days.~Patients will be treated serially: each patient will be followed for 2 weeks after cessation of PIF-1 administration before the next patient begins PIF-1 administration.
Study NCT01200420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: miravirsen
Description: SC injection
Study NCT01200420 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: SC injection
Study NCT02454179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Study NCT02454179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Study NCT01016977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene
Description: Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene
Study NCT01016977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene
Description: clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene
Study NCT02773875 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial pancreas system (Algorithm + CGM + pump)
Description: The AP system using fault detection algorithms will determine whether insulin infusion problems are occurring and may prevent severe hyperglycemia due to its predictive nature
Study NCT03939455 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Augmented Screening tool
Description: Tablet-based intervention
Study NCT00712309 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lifestent
Description: Stent for endovascular treatment of popliteal artery lesions
Study NCT00712309 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balloon-angioplasty (PTA)
Description: PTA for endovascular treatment of popliteal artery lesions
Study NCT01816854 — intervention group
Intervention type: DEVICE
Intervention: Stenting
Study NCT03490526 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Root canal disinfection with XP-endo Finisher
Description: The XP-Endo® finisher will be used next to the X-Smart Plus endodontic motor, with speed settings at 800rpm and torque at 1 N.cm. Irrigation with 17% EDTA and 2.5% NaOCl will be performed in three cycles of one minute each. In each cycle the XP-Endo will be used in the working length in continuous and slow movements of entrance and exit, with amplitude of 5mm, for a period of 1 minute, followed by new irrigation with 2.5ml of EDTA solution or hypochlorite of sodium 2,5%. Finally, the channel will be completely dry with absorbent paper tips
Study NCT03490526 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Root canal disinfection with passive ultrasonic irrigation
Description: For cleaning using passive ultrasonic irrigation, the E1 Irrisonic tip (Helse Ultrasonic, Ribeirão Preto, SP), will be used with Jetlaxis Sonic BP LED (Schuster, Santa Maria, RS). The insert has a diameter equivalent to a manual file 20, with reduced taper (0.01). The power used will be 10%. With root canals flooded with 17% EDTA, the irrigation tips will be coupled to the ultrasound and 1mm shorter than the working length. These tips will be kept in the center of the canal avoiding contact with the dentin walls. The irrigation will be performed in three cycles, and in each cycle the irrigation tips will be activated for 1 minute followed by new irrigation with 2.5ml EDTA. The same procedure will be repeated with 2.5% NaoCl. Finally, the channel will be completely dry with absorbent paper tips.
Study NCT00988195 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated Recombinant Human Arginase I
Description: Week 1 (Single Dose); Weeks 3 - 11 (Weekly Dose x 8 weeks)in 8 escalation doses
Study NCT00988195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Weeks 13-24 (once every 3 weeks)
Study NCT00473941 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive writing
Description: Behavioral intervention using writing about cancer to improve quality of life outcomes
Study NCT00473941 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Expressive writing
Description: Behavioral intervention using writing about cancer to improve quality of life outcomes
Study NCT04436939 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental implant
Description: Following dental implant installation, PEEK or Ti healing abutments were placed according to the split mouth study design.
Study NCT04436939 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental implant
Description: Following dental implant installation, PEEK or Ti healing abutments were placed according to the split mouth study design.
Study NCT00250679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arformoterol tartrate inhalation solution
Description: Arformoterol 15 ųg BID by nebulization
Study NCT00250679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arformoterol 25 ųg BID
Description: Arformoterol 25 ųg BID by nebulization
Study NCT00250679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol 12 ųg BID
Description: Formoterol fumarate 12 ųg BID via aerolizer/DPI
Study NCT00250679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo nebule or placebo aerolizer
Study NCT00250679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo nebule or placebo aerolizer
Study NCT01093521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg/m2 dose
Description: 5 day infusion of gallium nitrate (IV Ganite®) at a dose of 100 mg/m2/day
Study NCT01093521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg/m2 dose
Description: 5 day infusion of gallium nitrate (IV Ganite®) at 200 mg/m2/day
Study NCT03907410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nominal Financial Incentives
Description: The nominal financial incentives will consist of fixed-ratio incentives for each inhaled corticosteroids (ICS) actuation (25 cents for children on 4 daily ICS doses and 50 cents for children on 2 daily doses), with a maximum of $1 per day.
Study NCT03907410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily Adherence Reminders/Adherence Performance Feedback
Description: Study participants will receive automated daily text message or push notification reminders and automated weekly feedback summarizing their adherence performance through Way to Health, a mobile health, electronic monitoring platform.
Study NCT03907410 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Daily Adherence Reminders/Adherence Performance Feedback
Description: Study participants will receive automated daily text message or push notification reminders and automated weekly feedback summarizing their adherence performance through Way to Health, a mobile health, electronic monitoring platform.
Study NCT00884338 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endurance exercise
Description: The patients will carry out an endurance exercise program consisting of walking on a treadmill for 30 to 40 minutes at a speed corresponding to 80% of the maximum heart rate
Study NCT00884338 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Counseling
Description: Counseling about exercise and behavioural techniques to reduce fatigue
Study NCT01326234 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personalized Feedback
Description: The interactive program will provide assessment and personalized feedback on the participants' level of nicotine dependence, daily cigarette consumption, money spent on cigarettes, behavioral consequences of smoking, individual medical consequences of smoking, and family members' medical consequences of secondhand smoke.
Study NCT01326234 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Treatment as Usual
Description: Practitioners are able to provide normal care with regard to smoking; participants will complete the Treatment Fidelity Questionnaire to assess whether any smoking cessation interventions occurred
Study NCT03681197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 850 mg tablet will be started twice daily immediately at booking time and continued with induction by clomiphene citrate, it will be stopped once pregnancy is confirmed.
Study NCT03891108 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-986231 Formulation A
Description: Participants will be administered BMS-986231 Formulation A as IV infusion for 48 hours.
Study NCT03891108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986231 Formulation B
Description: Participants will be administered BMS-986231 Formulation B as IV infusion for 48 hours.
Study NCT03891108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986231 Formulation C
Description: Participants will be administered BMS-986231 Formulation C as IV infusion for 48 hours.
Study NCT03681197 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In placebo group,placebo will be strted twice daily at booking time and continued with induction by clomiphene citrate, it will be stopped once pregnancy is confirmed.
Study NCT03681197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene Citrate
Description: 50 mg of clomiphene citrate will be given starting day 2 of menstrual cycle for 5 days
Study NCT03891108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986231 Formulation D
Description: Participants will be administered BMS-986231 Formulation D as IV infusion for 48 hours.
Study NCT00577304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerin
Description: Individual pouch applicators containing 0.5 grams of Topical AmphiMatrix with Nitroglycerin. Each dose contains 4.5mg of Nitroglycerin. Each dose is intended for topical usage on both hands up to five minutes before an anticipated Raynaud's attack or up to 5 minutes after the beginning of an actual Raynaud's attack. Limited to four applications per day; minimum of two hours between applications.
Study NCT00577304 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Topical AmphiMatrix
Description: Individual pouch applicators containing 0.5 grams of Topical AmphiMatrix. Each dose is intended for topical usage on both hands up to five minutes before an anticipated Raynaud's attack or up to 5 minutes after the beginning of an actual Raynaud's attack. Limited to four applications per day; minimum of two hours between applications.
Study NCT00658359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Standard of care
Study NCT00658359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: CP-690,550 tablets dosed BID Months 12-72
Study NCT02989597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone Hydrochloride
Description: IV administration of methadone intra-operatively for a single dose
Study NCT02989597 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard pain regimen
Description: Standard medications for pain control administered after spinal surgery to be either fentanyl or morphine
Study NCT02989597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard pain regimen
Description: Standard medications for pain control administered after spinal surgery to be either fentanyl or morphine
Study NCT02989597 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Fusion Surgery
Description: Clinically-indicated spinal fusion surgery
Study NCT03681197 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clomiphene Citrate
Description: 50 mg of clomiphene citrate will be given starting day 2 of menstrual cycle for 5 days
Study NCT01146054 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CyberKnife based stereotactic radiotherapy
Description: 1. Initial orthogonal images will be obtained to confirm location of fiducial seeds.~2. Synchrony respiratory tracking system must be used to correct for respiratory associated tumor motion. This system utilizes a series of optical diodes placed upon the patient's chest wall. While the orthogonal images are obtained, the computer generates a model correlating the position of the chest wall with the position of the internal fiducials. This model is continuously updated during treatment to correct for subtle changes in tumor location.~3. Quality assurance will be performed as per standard practice at each participating institution.
Study NCT01146054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Treatment calculated per the needs of each patient and given at the instruction of the investigator; iv (intravenous).
Study NCT01146054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose (18F) (FDG)
Description: FDG-PET/CT scan is used in treatment planning. Treatment with 18F-FDG is calculated per the needs of each patient and given at the instruction of the investigator; iv
Study NCT03405441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-55375515 Dose Level 1
Description: Participants will receive JNJ-55375515 orally at a Dose level 1 in Part 1 of study.
Study NCT03405441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-55375515 Dose Level 2
Description: Participants will receive JNJ-55375515 orally at a Dose level 2 in Part 1 of study.
Study NCT02989597 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Fusion Surgery
Description: Clinically-indicated spinal fusion surgery
Study NCT02989597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Post operative swelling and pain control
Study NCT02989597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Post operative swelling and pain control
Study NCT03405441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-55375515 Dose Level 3
Description: Participants will receive JNJ-55375515 orally at a Dose level 3 in Part 1 of study.
Study NCT03405441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-55375515 Dose Level 4
Description: Participants will receive JNJ-55375515 orally at a Dose level 4 in Part 1 of study.
Study NCT03405441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-55375515 Dose Level 5
Description: Participants will receive JNJ-55375515 orally at a Dose level 5 in Part 1 of study.
Study NCT03405441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-55375515 Dose Level 6
Description: Participants will receive JNJ-55375515 orally at a Dose level 6 in Part 1 of study.